Targeting Set1B/COMPASS Pathway for Triple Negative Breast Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Set1B/COMPASS-associated cancers, particularly triple negative breast cancer, lack effective therapeutic targets as existing methods do not adequately address the overexpression of Set1B/COMPASS, which is correlated with poor survival outcomes in ER-negative patients.
Innovation Solution
Administering inhibitors of the Set1B/COMPASS pathway or agonists of negatively regulated targets, such as adiponectin receptor 1, to selectively inhibit triple negative breast cancer cell growth, while sparing ER-positive cells and normal epithelial cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatment methods are used for Set1B/COMPASS-associated cancers, then general cancer treatment is provided, but effective therapeutic targeting of Set1B/COMPASS overexpression is not achieved
Solution Approach 1:
The patent segments the cancer treatment approach by identifying and targeting the specific Set1B/COMPASS pathway that is overexpressed in certain cancer subtypes (particularly ER-negative breast cancers), rather than applying general cancer treatments. This segmentation allows for tailored therapeutic intervention based on the specific molecular characteristics of the tumor.
Solution Approach 2:
The patent applies local quality by developing therapies that specifically target cancers with Set1B/COMPASS overexpression while sparing other cancer types and normal cells. The treatment is localized to the specific molecular pathway that is dysregulated in the disease subset, providing precision medicine approach.
2Productivity
If Set1B/COMPASS pathway is inhibited to treat triple negative breast cancer, then tumor growth is suppressed, but potential side effects on normal cells expressing Set1B/COMPASS may occur
Solution Approach 1:
The patent employs partial action by targeting the overexpressed Set1B/COMPASS pathway specifically in cancer cells where it is dysregulated, rather than completely inhibiting the pathway in all cells. The therapy is designed to exploit the differential expression levels to achieve selective cancer cell killing while preserving normal cell function.
Solution Approach 2:
The patent utilizes parameter changes by focusing on the differential expression level of Set1B/COMPASS between cancer and normal cells. The therapeutic strategy is based on the parameter of overexpression, targeting the threshold where normal physiological function transitions to pathological overactivity.
3Reliability
If AdipoR1 agonists are administered to reactivate AdipoR1 signaling, then triple negative breast cancer cell survival is inhibited, but the mechanism's complexity increases
Solution Approach 1:
The patent introduces AdipoR1 agonists as intermediary molecules that reactivate the AdipoR1 signaling pathway, which is suppressed by Set1B/COMPASS overexpression. These agonists serve as mediators that translate the molecular signature (AdipoR1 suppression) into a therapeutic effect by restoring normal pathway function.
Data Source
AI summary
Disclosed are methods for treating Set1/COMPASS-associated cancers characterized by expression of Set1B/COMPASS. The methods typically include administering a therapeutic amount of an inhibitor of the Set1B/COMPASS pathway and/or an agonist for a target that is negatively regulated by the Set1B/COMPASS pathway.